Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
Intralesional nivolumab was safe and well-tolerated in this population of men with limited cutaneous KS.
Authors
- Timothy J. Henrich (ORCID: https://orcid.org/0000-0002-6684-0622)
- Alexander Bang (ORCID: https://orcid.org/0000-0002-1700-2411)
- Toby Maurer (ORCID: https://orcid.org/0000-0003-1968-3916)
- Rebecca Hoh (ORCID: https://orcid.org/0000-0001-5112-4220)
- Paul Couey
- Chia-Ching Wang
- Amelia N. Deitchman (ORCID: https://orcid.org/0000-0002-4722-463X)
- C. Wang (ORCID: https://orcid.org/0009-0002-9304-1217)
- Ursula E. Lang (ORCID: https://orcid.org/0000-0002-5376-4691)
- Kieron Seymour Leslie (ORCID: https://orcid.org/0000-0003-3504-2633)
- Steven G. Deeks (ORCID: https://orcid.org/0000-0001-6371-747X)
- Michiko Shimoda (ORCID: https://orcid.org/0000-0002-6627-4624)
- Sona Chowdhury
Institutions
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- JCO oncology advances.
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1200/oa-24-00098
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00